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Abstract
Asthma is a chronic inflammatory disease of the airways characterized by variable airway obstruction and airway
hyperresponsiveness (AHR). The T regulatory (Treg) cell subset is critically important for the regulation of immune
responses. Adoptive transfer of Treg cells has been shown to be sufficient for the suppression of airway inflammation in
experimental allergic asthma. Intervention strategies aimed at expanding the Treg cell population locally in the airways of
sensitized individuals are therefore of high interest as a potential therapeutic treatment for allergic airway disease. Here, we
aim to test whether long-term suppression of asthma manifestations can be achieved by locally expanding the Treg cell
subset via intranasal administration of a TLR-2 agonist. To model therapeutic intervention aimed at expanding the
endogenous Treg population in a sensitized host, we challenged OVA-sensitized mice by OVA inhalation with concomitant
intranasal instillation of the TLR-2 agonist Pam3Cys, followed by an additional series of OVA challenges. Pam3Cys treatment
induced an acute but transient aggravation of asthma manifestations, followed by a reduction or loss of AHR to
methacholine, depending on the time between Pam3Cys treatment and OVA challenges. In addition, Pam3Cys-treatment
induced significant reductions of eosinophils and increased numbers of Treg cells in the lung infiltrates. Our data show that,
despite having adverse acute effects, TLR2 agonist treatment as a therapeutic intervention induces an expansion of the Treg
cell population in the lungs and results in long-term protection against manifestation of allergic asthma upon subsequent
allergen provocation. Our data indicate that local expansion of Tregs in allergic airway disease is an interesting therapeutic
approach that warrants further investigation.
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Introduction
Allergic asthma is an inflammatory disease characterized by
airway hyperresponsiveness (AHR) to bronchospasmogenic com-
pounds, elevated allergen-specific IgE serum levels and chronic
airway eosinophilia. Th2 cells and the cytokines IL-4, IL-5 and IL-
13 produced by Th2 effector cells are known to be critical for the
induction of allergic asthma manifestations. Hence, allergic
asthma can be attributed to inadequate regulation of Th2 activity.
Several studies have shown that regulatory T (Treg) cells have the
ability to suppress allergic inflammation and asthma manifesta-
tions upon allergen provocation in mouse models of allergic
asthma. For instance, adoptive transfer of Treg cells into allergen-
sensitized mice down-regulates asthma manifestations [1], while
depletion of these cells exacerbates experimental asthma [2,3].
These data identify Treg cells as a potentially relevant target for
therapeutic intervention in allergic asthma and Treg cell-based
therapies are currently being considered for the treatment of this
complex disease [4]. Therapeutically, expansion of the endoge-
nous Treg cell population in allergen sensitized individuals is a
more attractive approach than adoptive transfer of ex vivo
expanded Treg cell subsets [5]. One possible approach to expand
the allergen-specific Treg cell subset in vivo is the triggering of Toll-
like receptor-2 (TLR-2) in the presence of antigen presentation [6].
Toll-like receptors are the best characterized class of pattern
recognition receptors of the innate immune system, and trigger
antimicrobial host defense responses [7]. TLRs recognize a wide
range of molecules expressed by invading pathogens, collectively
referred to as pathogen-associated molecular patterns (PAMPs).
For example, TLR-4 recognizes lipopolysaccharide, a cell wall
component of gram-negative bacteria. In contrast, TLR-2
recognizes a wide spectrum of PAMPs such as membrane
components of Gram-positive and -negative bacterial cell wall,
mycoplasma, mycobacteria, yeast and parasites [8].
TLR activation regulates the adaptive immune response by
affecting DC phenotype and function [7]. Upon interaction with
their ligand, TLR signaling induces DC maturation, up-regulation
of co-stimulatory molecules and pro-inflammatory cytokine
production [9]. In contrast, activation of certain TLRs such as
TLR-7 or TLR-9 [10,11] on plasmacytoid DCs has been shown to
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induce a tolerogenic phenotype. TLR activation therefore
represents a crucial regulatory mechanism to mount an adequate
adaptive immune response. TLRs are expressed by dendritic cells
and macrophages as well as numerous other cell-types such as T
cells, neutrophils, eosinophils, mast cells, monocytes and epithelial
cells [7].
Several TLRs have been reported to be expressed by Treg cells
and to modify their physiology [12,13]. For instance, TLR-4 and
25 enhance the suppressive capacities of Tregs [14,15], whereas
TLR-8 activation results in suppression of Treg functions [16].
TLR-2 signaling has been shown to induce Treg cell expansion
accompanied by a loss of suppressive activity in vitro and in vivo [6].
Interestingly, TLR-2 stimulated Tregs regain their in vivo suppres-
sive capacity over time [17].
We hypothesized that the TLR-2-driven expansion of Tregs
could be employed to increase their activity in allergen sensitized
mice resulting in reduced asthma manifestations upon subsequent
allergen provocations.
Here, we show that treatment of OVA sensitized mice with the
TLR-2 agonist Pam3Cys induces a mild and transient exacerba-
tion of asthma manifestations at the time of treatment. However,
this effect is associated with the acquisition of increased numbers of
CD4+CD25+Foxp3+ Treg cells in the lungs and long-term
protection to asthma manifestations upon secondary allergen
inhalation challenge.
Results
TLR-2 Triggering Induces a Trend Towards Reduced
Airway Hyperresponsiveness
It has been reported that Treg cells express TLR-2 and that
TLR-2 signaling induced by Pam3Cys at the time of TCR-
mediated Treg cell activation results in Treg proliferation, both
in vitro and in vivo [17]. However, TLR-2 signaling is also
associated with immunity enhancing effects. First, the TLR-2-
induced proliferation of Treg cells is accompanied by a transient
loss of their suppressive capacity [17]. Second, TLR-2 is also
expressed by numerous other cell types such as macrophages, DCs
and epithelial cells. In these cells TLR-2 triggering is known to
induce pro-inflammatory effects such as enhanced maturation of
DCs [7] and release of pro-inflammatory mediators by epithelial
cells [18]. Therefore, we designed an adapted asthma protocol
allowing us to circumvent the immediate pro-inflammatory effects
of TLR-2 stimulation by Pam3Cys. In this protocol, OVA-
sensitized mice were challenged by 4 OVA inhalations at 3 days
interval. Pam3Cys or PBS as a negative control was administrated
intranasally at 5 or 20 mg/mouse at the time of the 2 first
challenges only (Figure 1). One day after the last challenge, mice
were subjected to lung function measurements followed by section.
OVA challenge in control-treated mice induced typical AHR,
while mice that had received a Pam3Cys treatment at the first two
OVA inhalation challenges showed a trend towards a reduced
AHR (p= 0.10) (Figure 2a for the 20 mg/mouse dose of Pam3Cys).
No differences were observed between the two doses of Pam3Cys
tested in this experiment (data not shown).
TLR2 Activation does not Affect Allergic Inflammation in
the Lungs
To test whether the manifestations of allergic inflammation
were also reduced by local Pam3Cys treatment, we analyzed
OVA-specific IgE in serum and BAL cell counts. Remarkably,
mice treated with Pam3Cys had comparable levels of OVA-
specific IgE as PBS-treated control mice after OVA challenges
(Figure 2d). Also, the total numbers of cells in BAL were not
affected by the Pam3Cys treatment (Figure 2b). However,
differential cell counts showed that the proportion of eosinophils
was slightly but significantly decreased, while the fraction of
mononuclear cells was increased in the BAL of Pam3Cys-treated
mice (Figure 2c). Given the slight, not-significant increase and
substantial variance in total BAL cell numbers in the Pam3Cys
treatment group, this difference in eosinophil number is only
observed when analyzed as a fraction of BAL cells, not when
analyzed as total numbers of eosinophils in BAL. Of note, the
results with regard to eosinophil cell suppression (as fraction of
cells only) were identical with the two doses of Pam3Cys used (data
not shown). Taken together, these data indicate that local
Pam3Cys instillation at the first two out of four OVA inhalation
challenges has limited effects on both eosinophilic airway
inflammation and hyperresponsiveness.
Long-term Protection Against AHR by TLR-2 Triggering
To disentangle the acute effects of Pam3Cys administration
from the long-term effects, and to test whether our strategy could
provide long-term protection against AHR or airway eosinophilia,
we designed a new treatment protocol (Figure 1). In this protocol,
2 series of OVA challenges were performed in OVA sensitized
mice with a 3 week resting period in between to allow the
inflammation induced by the first series of challenges to resolve.
Pam3Cys was administered exclusively during the 1st series of
challenges (Figure 1). To evaluate the immediate and long-term
effects of TLR-2 activation, AHR was measured after both series
of OVA challenges.
After the first series of challenges, mice treated with Pam3Cys
displayed a moderate increase in AHR (Figure 3a). In contrast,
these Pam3Cys treated mice had a complete loss of AHR at the
second series of OVA challenges (in the absence of further TLR-2
activation) with overlapping responses between OVA- and PBS-
challenged mice in the Pam3Cys treated group (Figure 4a).
Long-term Effects of Pam3Cys Treatment on Allergic
Inflammation
Since we had not observed a pronounced effect of Pam3Cys
treatment on manifestations of allergic inflammation in our first
protocol, we assessed the OVA-specific IgE and BAL cell counts in
the long-term protocol both after the first and after the second
series of OVA challenges. As observed in the first experiment,
Pam3Cys treatment did not affect OVA-specific IgE levels in
serum (Figure 3d). This was observed immediately after the
Pam3Cys treatment, but also after the second series of OVA
inhalation challenges (Figure 4d). In line with these data, no
differences in IL-4 or IFNc levels were observed at either
timepoint in lung tissue of Pam3Cys and control-treated mice
(data not shown), indicating that the Pam3Cys treatment did not
induce a strong shift in the Th1/Th2 balance. To further analyze
a putative pro-inflammatory activation due to the local delivery of
Pam3Cys to the lungs, we also measured levels of TNFa, IL-6 and
IL17A in lung tissue, immediately after the Pam3Cys treatments
(timepoint 1). Here, we observed no difference between Pam3Cys
and control-treated mice for the levels of these pro-inflammatory
cytokines in lung tissue (Figure 3e).
Next, we checked whether eosinophilic infiltration in the
airways was affected by TLR-2 activation at the time of OVA
challenge. Immediately after Pam3Cys treatment, total cell counts
showed a tendency to increase in the Pam3Cys-treated group
compared to control (Figure 3bc). Interestingly, neutrophils
infiltration was significantly increased in Pam3Cys-treated animals
(Figure 3c). After the second series of OVA challenges, total cell
numbers in BAL were similar between the Pam3Cys-treated and
TLR-2 Agonist Induces Lung Tregs and Loss of AHR
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the control group (Figure 4b), but eosinophil numbers were
significantly reduced in mice that had received prior Pam3Cys
treatment (Figure 4c). Interestingly, analysis of lung tissue cytokine
levels revealed increased levels of IL-10, but not of TGFb in lung
tissue at the later timepoint (Figure 4e).
CD25+Foxp3+ T Regulatory Cells in the Lung
Compartment
To check whether the beneficial effects of Pam3Cys treatment
on asthma manifestations could have been mediated by an
increased presence of Treg cells, we measured by flow cytometry
the numbers of CD4+CD25+Foxp3+ cells in the BAL infiltrates.
After the OVA inhalation challenges with Pam3Cys treatment, the
proportion of CD25+Foxp3+ cells in the CD4+ population had
increased from 11.060.7% to 17.761.3%, (Figure 5a). Interest-
ingly, this increased presence of Treg cells in the BAL of Pam3Cys
treated mice was still observed after the second series of challenge
(Figure 5b), although the differences were less pronounced. This
indicates that TLR-2 activation at the time of allergen provocation
induced the long-term presence of an increased population of
regulatory T cells.
Discussion
Severity of allergic inflammation and AHR in allergic asthma
are tightly correlated to the activity of Treg cells, and therapeutic
strategies aimed at inducing the expansion of endogenous allergen-
specific Treg populations are an attractive future alternative for
current treatment options [4,5]. In this study, we tested whether
expansion of Treg cells via TLR-2 activation at the time of
allergen challenge can result in long-term protection against
asthma manifestations in the mouse. To this end, we treated mice
at the time of OVA inhalation challenges with Pam3Cys, a TLR-2
agonist that has been shown to induce Treg cell expansion
[6,17,19]. We observe a decreased AHR and lung eosinophilia in
mice that received prior treatment with the TLR-2 agonist. This
effect was initially observed for airway eosinophilia shortly after
cessation of Pam3Cys treatment with two different doses of
Pam3Cys, whilst the results for AHR showed only a trend towards
a reduction in the Pam3Cys treatment groups (protocol 1; Figure 2
and data not shown). However, at prolonged periods after
withdrawal of the TLR-2 agonist, lung eosinophilia and AHR
were both effectively suppressed upon allergen challenge (protocol
2; Figure 4). Remarkably, AHR was suppressed to the level of
PBS-challenged mice at this later timepoint. Since we used an
indirect non-invasive measurement of lung function, we cannot
draw definite conclusions regarding the airway resistance in our
experiments [20]. Nevertheless, we interpret this striking difference
in the substitute Penh parameter as a strong indication for an
actual difference in lung function between the Pam3Cys-treated
group and the control-treated mice.
The effects of Pam3Cys treatment were associated with
increased amounts of CD4+CD25+Foxp3+ Treg cells in the BAL
at both timepoints, which is in agreement with earlier observations
that in contrast to allergen-specific IgE and airway eosiniphilia,
AHR is highly sensitive to the presence of lung-resident Foxp3+
regulatory T cells [21]. Notwithstanding the induction of this
protective response, AHR was exacerbated and lung neutrophilia
was induced at the time of TLR-2 activation (Figure 3), indicating
that the acute and the long-term effects of Pam3Cys treatment
were strongly divergent.
The contrasting results of the acute and long-term effects of
TLR-2 activation can be explained by the cells responsible for
relaying the Pam3Cys induced signal. Mouse alveolar macro-
phages, which reside in the alveoli under steady state conditions,
express TLR-2 and Pam3Cys treatment induces expression of pro-
inflammatry cytokines like IL-6 and TNFa in vitro [22]. Airway
epithelial cells of the mouse also express TLR-2 [23], and
Pam3Cys treatment induced KC expression in vitro [24]. Interest-
ingly, activation of TLR-2 in airway epithelial cells has been
shown to induce pro-inflammatory cytokine production [25] as
well as cleavage of the tight junction protein occludin and the
adherens junction protein E-cadherin, allowing transepithelial
migration of inflammatory cells [26]. Finally, airway smooth
muscle cells will induce IL-8 expression upon TLR-2 activation
[27]. Moreover, both eosinophils and neutrophils express TLR-2,
and activation of TLR-2 on eosinophils induces the expression of
IL-1b, IL-6, IL-8 and GROa, and induces release of eosinophilic
cationic protein (ECP) [28]. In dendritic cells, Pam3Cys treatment
has been shown to induce IL-6 and IL-10 responses and repress
Figure 1. Time schedule of the experimental procedures. Days of sensitization, OVA/PBS challenges, Pam3Cys/PBS treatments and lung
function measurements/section are indicated for both the short protocol (A) and the long-term protocol (B).
doi:10.1371/journal.pone.0055307.g001
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IL-12 expression, thereby favoring Th2 activity [29,30]. Hence, at
the time of the first OVA inhalation challenges in both protocols,
TLR-2 agonist could be hypothesized to result in the induction of
a pro-inflammatory response by the structural and lung resident
cells. Nevertheless, we do not see induction of pro-inflammatory
cytokines such as TNFa, IL-6 and IL17A (Figure 3) or suppression
of IL-10 or TGFb (Figure 4) in lung tissue directly after Pam3Cys
treatment, indicating that the induction of neutrophilic inflamma-
tion does not reflect a generalized pro-inflammatory activation of
the airways by Pam3Cys. Clearly, further research is needed to
identify the cellular intermediates through which Pam3Cys
induces both neutrophilic inflammation and increased AHR.
Here, use of adoptive transfer of wild-type BM cells into
sublethally irradiated TLR-2-deficient mice might allow identifi-
cation of the critical cell population for the Pam3Cys-induced
effects.
At the same time, Pam3Cys likely acts directly on regulatory T
cells,which has been shown to induce expansion and transient loss
of suppressive capacity of the Tregs [6,17], although the TLR-2-
induced loss of suppression by Tregs was recently challenged [19].
In our study, the number of Treg cells in the BAL was
dramatically increased at the time of Pam3Cys treatment, in line
with the reported direct proliferative effect of Pam3Cys on Treg
cells (Figure 5). Since we observe exacerbated asthma manifesta-
tions at this timepoint, it can be inferred that these TLR-2-
expanded Treg cells displayed a reduced suppressive capacity, as
shown before [6,17]. Nevertheless, from our data we cannot
exclude that the expanding Tregs have bona fide suppressive activity
[19], and are merely insufficient in number to functionally repress
the TLR-2-induced exacerbated asthma manifestations. We find,
however, that the effects of TLR-2 agonist treatment on
neutrophilic airway inflammation are lost as soon as 7 days after
the last treatment (protocol 1). Remarkably, even after 3 weeks, the
expanded Treg subset is retained and has apparently full
functionality, resulting in increased levels of lung tissue IL-10,
slightly suppressed allergic inflammation and the complete absence
Figure 2. Airway responsiveness, BAL cell counts and composition, and OVA-specific IgE serum levels. Mice (n = 8) were sensitized with
OVA/Alum and received 4 OVA or PBS inhalation challenges. TLR-2 agonist (20 mg per mouse in PBS) or PBS was administered intranasally 1 hour
before the 2 first challenges. Asthma manifestations were measured one day after the last challenge. A: Airway responsiveness to increasing doses of
methacholine was measured by whole-body plethysmography and is expressed as enhanced pause (PenH) (gray symbols: PBS-challenged groups,
white symbols: OVA-challenged groups, squares: Pam3Cys-treated groups, triangles: PBS-treated groups). B, C: total (B) and differential (C) cell counts
in the BAL of PBS and OVA-challenged mice as indicated. D: OVA-specific IgE levels in the serum of PBS and OVA-challenged mice as indicated. All
values are displayed as average 6 SEM.
doi:10.1371/journal.pone.0055307.g002
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Figure 3. Airway responsiveness, lung cell infiltration and OVA-specific IgE serum levels. Mice (n = 8) were sensitized with OVA/Alum and
received 3 OVA or PBS inhalation challenges. TLR-2 agonist (20 mg per mouse in PBS) or PBS was administered intranasally 1 hour before each
challenge. Asthma manifestations were measured one day after the last challenge. A: Airway responsiveness to increasing doses of methacholine was
measured by whole-body plethysmography and is expressed as enhanced pause (PenH) (gray symbols: PBS-challenged groups, white symbols: OVA-
challenged groups, squares: Pam3Cys-treated groups, triangles: PBS-treated groups). B, C: total (B) and differential (C) cell counts in the BAL of OVA-
challenged mice. D: OVA-specific IgE levels in the serum of OVA-challenged mice. (E) Lung tissue cytokines measured in lung homogenates of PBS or
Pam3Cys (P3C) treated mice as indicated. All values are displayed as average 6 SEM (panels A–D) or individual values (dots)+mean (bar) (panel E).
Significance is indicated (*) when p,0.05.
doi:10.1371/journal.pone.0055307.g003
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Figure 4. Airway responsiveness, lung cells infiltration and OVA-specific IgE serum levels. Mice (n = 8) were sensitized with OVA/Alum
and received a first series of 3 OVA inhalation challenges, during which TLR-2 agonist (20 mg per mouse in PBS) or PBS was administered intranasally 1
hour before challenge. After 3 weeks, mice received a second series of 3 inhalation challenges (OVA or PBS). Asthma manifestations were measured
one day after the last challenge. A: Airway responsiveness to increasing doses of methacholine was measured by whole-body plethysmography and
is expressed as enhanced pause (PenH) (gray symbols: PBS-challenged groups, white symbols: OVA-challenged groups, squares: Pam3Cys-treated
groups, triangles: PBS-treated groups). B: total cell counts in the BAL of PBS and OVA-challenged mice as indicated. C: differential cell counts in the
BAL of OVA-challenged mice only. D: OVA-specific IgE levels in pre-challenge and post-challenge sera of OVA-challenged mice. (E) Lung tissue
cytokines measured in lung homogenates of PBS or Pam3Cys (P3C) treated mice after OVA challenge at timepoint 1 (left-hand panel) or at timepoint
2 (right-hand panel) as indicated. All values in panels A–D are displayed as average 6 SEM, panel E displays individual values (dots)+mean (bar).
Significance is indicated (*) when p,0.05.
doi:10.1371/journal.pone.0055307.g004
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of an AHR response upon OVA challenge. Therefore, treatment
with Pam3Cys induced a long term protection against AHR, and
this effect was associated with the presence of higher numbers of
lung Foxp3+ Treg cells.
Our findings are in line with previous observations AHR is
more sensitive to the presence of lung-resident Foxp3+ regulatory
T cells than allergen-specific IgE or airway eosinophilia in
experimental mouse models of allergic asthma [21]. Nevertheless,
studies addressing the role of regulatory T cells in experimental
mouse models of asthma have yielded widely divergent results,
with some studies observing mainly suppression of AHR [21],
some mainly of eosinophils [1,31,32], some studies reporting no or
little effect at all [33], and finally some reporting strongly strain-
dependent effects of Tregs [2]. This discrepancy between studies
might well stem from differences in experimental approach,
genetic background and treatment regimen used in the various
Figure 5. CD25+FoxP3+ CD4+ T cells in BAL. Total cells in the BAL isolated at both timepoints of protocol 2 (Figure 1b) were stained for CD4,
CD25 and FoxP3, and analyzed by flowcytometry. A. FACS staining profiles for representative FACS plots of the four groups analyzed at timepoint 2.
Forward and Side scatter profiles are used to define lymphocytes, CD4-PerCP/FoxP3-PE was used to identify FoxP3+ regulatory T cells. (B, C) Number
of CD25+FoxP3+ cells is shown as a fraction of the total CD4+ T cell count. B: the fraction of CD25+FoxP3+ cells within the CD4+ T cells from lung 24 h
after the last of three OVA challenges in the presence or absence of Pam3Cys, as indicated. C: the fraction of CD25+FoxP3+ cells within the CD4+ T
cells from lung 24 h after the last of three OVA or PBS challenges, three weeks after the first series of challenges as depicted in panel A. Treatment at
the first series of challenges is indicated on the X-axis. All values are displayed as average 6 SEM. Significance is indicated (*) when p,0.05 or
(***) when p,0.005.
doi:10.1371/journal.pone.0055307.g005
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studies. Clearly, further experiments are required to functionally
assess the critical requirement for the expanded Treg cell subset on
the strong effects on AHR and the relatively mild effects on airway
eosinophilia we observe after Pam3Cys treatment.
Studies aiming at the role of TLR-2 signaling in experimental
asthma have yielded contrasting results, showing either beneficial
or aggravating effects (see ref. [34] for review). These discrepancies
are partly due to the fact that various experimental models have
been studied, using either TLR-2/21 or TLR-2/26 agonists, and
using TLR-2 activation during either allergic sensitization or
allergen challenge, or even at a distant anatomical location [34].
Importantly, the role of CD4+CD25+Foxp3+ Treg cells was never
investigated in these experiments. In our study, we could
discriminate the immediate and long-term effects of TLR-2
stimulation, and find that these effects are strongly divergent.
This duality in the effects of TLR-2 activation may also explain
some of the disparate results previously published concerning the
role of TLR-2 in experimental asthma. For instance, Redecke
et al. reported an exacerbation of asthma manifestation in mice
treated with TLR-2 agonist at the time of subcutaneous
sensitization [35]. In contrast, when mice received Pam3Cys
intraperitoneally during the challenge phase, asthma manifesta-
tions were reduced, which was associated with an IL-12 dependent
increase in Th1 activity [36]. The timing and anatomical location
of Pam3Cys application are thought to be responsible for the
induction of a Th1 response, since these authors also mention an
exacerbated asthma phenotype upon intranasal Pam3Cys inocu-
lation. Nevertheless, the observed suppression of asthma manifes-
tations was independent of IL-10 or TGFb, indicating a lack of
involvement of antigen-specific Tregs that can be explained by the
distant anatomical location of OVA (intranasal) and Pam3Cys
(intraperitoneal) administration [36]. In our study, we specifically
show that expansion of lung Treg cells via TLR-2 activation at the
time of allergen challenge is associated with long-term protection
against asthma manifestations in the mouse. However, our study
also has some shortcomings, such as the lack of a significant
suppression of AHR in the first Pam3Cys treatment protocol and
the lack of histological evaluation of mucus production in all our
experiments, which precludes any conclusions to be drawn on this
highly relevant asthma parameter.
In conclusion, we show that local TLR-2 activation at the time
of allergen challenge results in slightly exacerbated asthma
manifestations at the time of treatment, while rendering a long-
lasting protection against AHR and allergic inflammation upon
allergen provocation at later time points. These data further
strengthen the validity of approaches aimed towards in situ




This study was performed in strict accordance with the national
and European regulations for the care and use of laboratory
animals. Animal care and use were evaluated and approved of by
the Institutional Animal Care and Use Committee of the
University of Groningen (IACUC-RuG; permit numbers 5109
and 4253). Specific pathogen-free (according to the Federation of
European Laboratory Animal Science Associations) male BALB/c
mice (6–8 wk old) were purchased from Charles River (Maastricht,
The Netherlands) and housed in macrolon cages in a laminar flow
cabinet and provided with food and water ad libitum.
Mouse Models of Asthma
We used two adapted protocols (Figure 1) based on our
standard OVA-driven mouse model for experimental allergic
asthma [37]. In brief, mice were sensitized intraperitoneally (i.p.)
on days 0 and 7 with 10 mg OVA (grade V, Sigma-Aldrich,
Zwijndrecht, Netherlands) in 2.25 mg Alum adjuvant (Pierce,
Rockford, Illinois). After two weeks, sensitized mice were exposed
to four OVA (10 mg/ml in saline) or saline inhalation challenges
for 20 min every third day in Protocol 1. In this experiment, mice
were treated by intranasal (i.n.) administration of 20 mg Pam3Cys-
SKKK (MCA Microcollection GmbH, Germany; endotoxin-free,
reconstituted in endotoxin-free water under sterile conditions and
stored at –20uC in single-use aliquots) 1 h before the first two of
the four OVA inhalation challenges. In protocol 2, mice received 2
series of OVA inhalation challenges, starting 2 weeks after the last
i.p. injection. Each series consisted of 3 challenges every third day,
and the 2 series were performed at a 3 week interval. Mice were
treated by i.n. administration of 20 mg Pam3Cys-SKKK 1 h
before the first series of OVA inhalation challenges only, the dose
of Pam3Cys-SKKK for intranasal application was based on [38].
Measurement of Airway Responsiveness in vivo
Twenty-four hours after the last OVA challenge of each series,
airway responsiveness was measured in conscious, unrestrained
mice using barometric whole-body plethysmography by recording
respiratory pressure curves (Buxco, EMKA Technologies, Paris,
France) in response to increasing doses of inhaled methacholine
(Sigma-Aldrich). Airway responsiveness was expressed in en-
hanced pause (Penh), as described in detail previously [39].
OVA-specific IgE ELISA
After measurement of airway responsiveness in vivo, mice were
anaesthetized and bled by cardiac puncture. Subsequently, serum
was collected and stored at –80uC until analysis. Serum levels of
OVA-specific IgE were measured by sandwich ELISA as
described previously [40]. A reference standard was used with
arbitrary units of 1,000 EU/ml. The detection level of the ELISA
was 0.5 EU/ml for OVA-specific IgE.
Differential Cell Counts in the Bronchoalveolar Lavage
Fluid
Bronchoalveolar lavage (BAL) was performed immediately after
bleeding of the mice by five injections of 1 ml saline (37uC)
through a tracheal cannula into the lungs. Cells in the BAL were
centrifuged and resuspended in PBS. The total number of cells in
the BAL was determined using a Bu¨rker-Tu¨rk counting-chamber
(Karl Hecht Assistent KG, Sondheim/Ro¨hm, Germany). For
differential BAL cell counts, cytospin preparations were prepared
(156g, 5 min, 4uC, Kendro Heraues Instruments, Asheville,
North Carolina, US). Next, cells were fixed and stained with
Diff-Quick (Dade A.G., Du¨dingen, Switzerland). Per cytospin, 400
cells were counted and differentiated into mononuclear cells,
eosinophils, and neutrophils by standard morphology and staining
characteristics.
Flow Cytometry
For FoxP3 staining, BAL cells permeabilized according to the
manufacturer’s instructions (FoxP3 staining kit; eBioscience, San
Diego, California, US) and stained with anti-CD4Per-CP (clone
RM4-5; Pharmingen BD, Breda, the Netherlands), anti-CD25APC
(clone PC61; Pharmingen BD) and anti-Foxp3PE (clone FJK-16;
eBioscience). After staining, cells were analyzed with FACScanTM
flow cytometer (Becton Dickinson) using CELLQuestTM software.
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Statistical Analysis
All data are expressed as mean 6 standard error of mean
(SEM). The airway dose-response curves to methacholine were
statistically analyzed by a general linear model of repeated
measurements (2-way ANOVA) followed by post-hoc comparison
between groups. Statistical analysis on BAL cell counts and ELISA
were performed using a Student’s t-test (2-tailed, homosedastic).
Results were considered statistically significant at the p,0.05 level.
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